Overview

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

This trial is a multicenter, single-arm, phase II study evaluating the efficacy of pembrolizumab and bevacizumab in combination with platinum-based chemotherapy (PBC) followed by pembrolizumab, bevacizumab and olaparib as a maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.This study is planned to enroll eligible 35 patients from multiple study sites in Japan.

Phase:

Phase 2

Details

Lead Sponsor:

Kosei Hasegawa

Treatments:

Bevacizumab
Carboplatin
Docetaxel
Olaparib
Paclitaxel
Pembrolizumab